



NEWS RELEASE

ALLIANCE GROWERS ADVANCES ON ITS PROJECTS

September 6, 2019 – Vancouver, BC – Alliance Growers Corp. (CSE: ACG; FWB:1LA; OTCQB: ALGWF) (“Alliance Growers” or “the Company”), announces its advancements on its business development and financing initiatives. The Company’s strategic partner on the Cannabis Biotech Complex, Pharmagreen Biotech Inc., establishes quality advisory board as Pharmagreen carries out their financial marketing initiatives aimed at U.S private investors, institutions and funds. Alliance is finalizing terms on an exclusive Canadian distributorship of technology and expertise that provides cleaning and disinfecting processes to help cultivators protect their crops against mould and spores.

Pharmagreen Biotech Inc. (OTC: PHBI), forms Independent Advisory Board

On September 03, 2019, announced the formation of its independent advisory board. Two practicing specialists in Cardiology bring their professional insight to provide the company with very valuable data that will be used in future extraction and formulations of cannabinoids under the Pharmagreen brand. Dr. Archer Baskerville, MD, FACC, FSCAI from Virginia, United States, and Dr. Wladyslaw Wojcik MD, FRCP from Saskatchewan, Canada. will serve as advisory board members advising Pharmagreen on developments in the medical industry regarding the adaptation of cannabinoid use, especially CBD in the treatment of individuals. See Pharmagreen News release for more information.

Peter Wojcik, CEO of Pharmagreen has been active in the US making presentations to various funds and institutional investors for the past few weeks, now that Pharmagreen is a reporting issuer with the SEC.

Alliance is finalizing terms with Irish Sea Organics for an exclusive Canadian distributorship

Hypochlorous Acid (“HOCL”) production equipment and the unique applications are used for high-volume, industrial and commercial applications, specifically bacteria, mould, and spore control. The introduction of HOCL to any size of cultivation or processing business operation, combines proven efficacy and performance with vital cost benefits to the end user.

The proposed agreement includes income from equipment and consumable product sales, consultancy and service contracts, and a royalty stream. Alliance Growers has spent considerable time investigating the opportunity to add this technology and process of cleaning and sterilisation for the Canadian Cannabis and wider Agricultural industry sector to its business model of providing products and services to the cannabis and hemp growers.

Combined margins on the initial equipment, consumables and service agreements could be as high as 40% with smaller cannabis cultivation operations and up to 30% with larger producers. Up front capital costs for Alliance are not expected to be excessive as the purchasers of the equipment and related consumables cover the bulk of those costs.

Commenting on Alliance advancements Dennis Petke, President and CEO of Alliance Growers stated, “The establishment of an advisory board and the financing initiatives now underway with Pharmagreen brings us one step closer to the construction of the Cannabis Biotech Complex.

Mr. Wojcik will be providing Alliance with an update next week. After completing further extensive due diligence on the HOCL technology and process, we realize that this could be the most cost-effective green solution to many key issues facing the cannabis industry today. This technology fits with our existing model of providing services to cultivators and furthers our goal of establishing a long-term presence in the cannabis industry through diversity, science and technology. To further the Company's growth and to create value for shareholders, we encourage warrant holders to take advantage of the Warrant Incentive Program as this is a very important first step in launching our financing initiatives that will allow Alliance to continue to execute on its business plan. We thank our many loyal shareholders and other stakeholders for their continued support and patience as we execute on our business plan in this evolving and often volatile cannabis market."

Alliance to benefit along with Pharmagreen in the rapidly evolving CBD industry

Alliance is exploring opportunities with Pharmagreen to benefit from the rapidly evolving CBD industry. Pharmagreen is highly focused on the CBD industry by developing supply chain for CBD hemp growers utilizing the CBD Dana hemp strain. Pharmagreen's model is to provide the hemp farmers the highest quality starter female plantlets to produce the highest quality of biomass for the production of CBD formulations for human and animal use. Pharmagreen's ability to supply high CBD starter plantlets along with high level of expertise in farming the strain provides a very lucrative high CBD hemp farming opportunity for the farmers by making highly efficient use of land. Higher profits and higher yields can be generated for example from 10 acres with Pharmagreen's high CBD strain and farming techniques than from farming 1,000 acres using standard industrial hemp from seed. The end product using Pharmagreen's CBD strain and farming techniques ultimately provides the highest quality, medical grade, flower tops biomass.

About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.

WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC: PHBI) company. WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a proprietary tissue culture process with opportunity to become one of the largest players globally. Pharmagreen's mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of cannabis and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors. For further information on the company progress on the construction of a 63,000 ft² state of the art "Cannabis Biotech Complex" please visit www.pharmagreen.ca

About Irish Sea Organics

Irish Sea Organics breakthrough technology is revolutionizing seed, plant, harvest, drying and raw material extraction processes. Hypochlorous water or HOCL is electrolyzed water manufactured by the human body that is used by white blood cells to eliminate waste and destroy foreign substances like bacteria, fungus and viruses. There is no known resistance of any organism to its effects, and there are demonstrated kill rates for this product that are FDA and EPA registered and certified. For further information on the Irish Sea Organics, please visit the company's website at www.irishseaorganics.com/.

About Alliance Growers Corp.

Alliance Growers is a Diversified Global Medical Cannabis Company driven by the Company's 'Four Pillars' Organization Plan – Cannabis Biotech Complex (services to cultivators), Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Technology.

Alliance Growers is working with Pharmagreen Biotech Inc. to jointly develop and operate a 63,000-square foot Cannabis Biotech Complex, to be the first of its kind in Western Canada to house a DNA Botany lab, CBD extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general.

For further information, please visit the Company's website at www.alliancegrowers.com or the Company's profile at www.sedar.com.

If you would like to be added to Alliance Growers' news distribution list, please send your email address to newsletter@alliancegrowers.com.

For more information contact:

Dennis Petke
CEO, President and Director
Tel: 778-331-4266
DennisPetke@alliancegrowers.com

Rob Grace
Communications Consultant
Tel: 778-998-5431
RobDGrace@gmail.com

FOLLOW US:



THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news

release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.